DK3150610T3 - Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on - Google Patents

Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on Download PDF

Info

Publication number
DK3150610T3
DK3150610T3 DK16183844T DK16183844T DK3150610T3 DK 3150610 T3 DK3150610 T3 DK 3150610T3 DK 16183844 T DK16183844 T DK 16183844T DK 16183844 T DK16183844 T DK 16183844T DK 3150610 T3 DK3150610 T3 DK 3150610T3
Authority
DK
Denmark
Prior art keywords
azepino
polymorphs
indol
methylamino
tetrahydro
Prior art date
Application number
DK16183844T
Other languages
Danish (da)
English (en)
Inventor
Patricia Ann Basford
Adam Gillmore
Matthew Cameron Jones
Robert Walton
Anthony Michael Campeta
Eleftherios Kougoulos
Suman Luthra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43859823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3150610(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3150610T3 publication Critical patent/DK3150610T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16183844T 2010-02-12 2011-02-10 Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on DK3150610T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30427710P 2010-02-12 2010-02-12
EP11708094.5A EP2534153B2 (en) 2010-02-12 2011-02-10 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Publications (1)

Publication Number Publication Date
DK3150610T3 true DK3150610T3 (da) 2019-11-04

Family

ID=43859823

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16183844T DK3150610T3 (da) 2010-02-12 2011-02-10 Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
DK11708094.5T DK2534153T4 (da) 2010-02-12 2011-02-10 Salte og polymorfer af 8-fluor-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-on

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11708094.5T DK2534153T4 (da) 2010-02-12 2011-02-10 Salte og polymorfer af 8-fluor-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-on

Country Status (32)

Country Link
US (5) US8754072B2 (enExample)
EP (4) EP3597651A1 (enExample)
JP (6) JP5745283B2 (enExample)
KR (2) KR20120127495A (enExample)
CN (2) CN102884066B (enExample)
AR (2) AR080164A1 (enExample)
AU (1) AU2011213944B2 (enExample)
BR (1) BR112012019050B1 (enExample)
CA (2) CA3024216C (enExample)
CY (3) CY1118319T1 (enExample)
DK (2) DK3150610T3 (enExample)
ES (2) ES2607806T5 (enExample)
FI (1) FI2534153T4 (enExample)
FR (1) FR18C1049I2 (enExample)
HR (2) HRP20161742T4 (enExample)
HU (3) HUE030969T4 (enExample)
IL (1) IL220921B (enExample)
LT (3) LT3150610T (enExample)
LU (1) LUC00093I2 (enExample)
MX (1) MX343383B (enExample)
NL (1) NL300958I2 (enExample)
NO (1) NO2018039I1 (enExample)
NZ (1) NZ601445A (enExample)
PL (2) PL2534153T5 (enExample)
PT (2) PT3150610T (enExample)
RS (2) RS55487B2 (enExample)
RU (1) RU2570198C2 (enExample)
SG (2) SG182533A1 (enExample)
SI (2) SI3150610T1 (enExample)
SM (3) SMT201600462T1 (enExample)
TW (1) TWI545123B (enExample)
WO (1) WO2011098971A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3150610T3 (da) 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
TW201516636A (zh) * 2013-10-22 2015-05-01 Hon Hai Prec Ind Co Ltd 電子裝置及其供電方法
NZ728392A (en) * 2014-08-22 2023-06-30 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
US20190276405A1 (en) * 2016-05-16 2019-09-12 Pulmagen Therapeutics (Asthma) Limited Crystal of quinoline derivative
DE102016218772A1 (de) * 2016-09-28 2018-03-29 Bruker Biospin Gmbh Verbesserte Temperierung eines NMR-MAS-Rotors
ES2985767T3 (es) 2017-01-24 2024-11-07 Assia Chem Ind Ltd Formas en estado sólido de rucaparib y de sales de rucaparib
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
JP2021501771A (ja) * 2017-11-03 2021-01-21 サンド・アクチエンゲゼルシヤフト 三環系ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤の結晶性塩
WO2019115000A1 (en) * 2017-12-15 2019-06-20 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
JP7356450B2 (ja) 2018-01-05 2023-10-04 サイブレクサ １・インコーポレイテッド 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
WO2019207498A1 (en) * 2018-04-25 2019-10-31 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
EP3873905A4 (en) 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING COMPOUNDS AND THEIR USE AS KINASE ATR INHIBITORS
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
BR112022000337A2 (pt) 2019-07-10 2022-04-12 Cybrexa 2 Inc Conjugados de peptídeos de citotoxinas como terapêuticos
CN111004244A (zh) * 2019-12-27 2020-04-14 重庆市碚圣医药科技股份有限公司 一种瑞卡帕布樟脑磺酸盐的合成方法
EP4100125A1 (en) 2020-02-03 2022-12-14 Sandoz AG Polymorph of rucaparib mesylate
AU2021260109B2 (en) * 2020-04-24 2024-07-11 Astrazeneca Ab Pharmaceutical formulations
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
CA3185209A1 (en) 2020-07-10 2021-01-27 Alyssa WINKLER Gas41 inhibitors and methods of use thereof
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
TW202304447A (zh) 2021-04-08 2023-02-01 瑞士商瑞森製藥公司 聚（ａｄｐ－核糖）聚合酶抑制劑
US20250223295A1 (en) 2022-01-11 2025-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023152754A1 (en) * 2022-02-08 2023-08-17 Sawant, Mohit Manikrao Crystalline form of rosuvastatin allyl ester
EP4626867A1 (en) * 2022-11-30 2025-10-08 Ideaya Biosciences, Inc. 2-oxoquinazoline crystalline forms

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489011A (en) 1983-05-16 1984-12-18 Merrell Dow Pharmaceuticals Inc. Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
ID22799A (id) 1997-02-03 1999-12-09 Pfizer Prod Inc Turunan-turunan asam arilsulfonilamino hidroksamat
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
BR9807678A (pt) 1997-02-11 2000-02-15 Pfizer Derivados de ácidos arilsulfonil-hidroxâmicos
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US5835420A (en) 1997-06-27 1998-11-10 Aplus Flash Technology, Inc. Node-precise voltage regulation for a MOS memory system
CN1171866C (zh) 1997-08-08 2004-10-20 辉瑞产品公司 芳氧基芳基磺酰氨基异羟肟酸衍生物
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
EA005889B1 (ru) 1997-11-11 2005-06-30 Пфайзер Продактс Инк. Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DE69915004T2 (de) 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
EA006294B1 (ru) 1998-12-23 2005-10-27 Дж.Д.Сирл Энд Ко. Применение комбинации целекоксиба и гемцитабина в комбинированном способе лечебного воздействия при лечении рака поджелудочной железы
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
KR100452491B1 (ko) 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
KR20040011751A (ko) 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR20050085835A (ko) † 2002-12-19 2005-08-29 화이자 프로덕츠 인코포레이티드 Ｅ-2-메톡시-ｎ-（3-｛4-［3-메틸-4-（6-메틸-피리딘-3-일옥시）-페닐아미노］-퀴나졸린-6-일｝-알릴）-아세트아마이드의 착물, 및 그의 제조방법 및 용도
MXPA05010563A (es) 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
ES2339663T3 (es) 2003-07-25 2010-05-24 Cancer Research Technology Limited Inhibidores de parp triciclicos.
PT1794163E (pt) * 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
BRPI0515567A (pt) 2004-09-22 2008-07-29 Pfizer combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase
CN101384264B (zh) * 2004-09-22 2012-03-14 辉瑞大药厂 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
ES2382950T3 (es) * 2004-09-22 2012-06-14 Pfizer, Inc. Formas polimorfas de la sal de fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepin[5,4,3-cd]indol-6-ona
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
KR100843401B1 (ko) 2006-12-04 2008-07-04 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
WO2008068615A1 (en) * 2006-12-06 2008-06-12 Pfizer Inc. Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
WO2008114114A2 (en) † 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
EP2065385A1 (en) † 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EP2231648A1 (en) * 2007-12-05 2010-09-29 BIAL - Portela & Ca., S.A. New salts and crystal forms
KR20090060674A (ko) 2007-12-10 2009-06-15 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
WO2009087381A1 (en) † 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
SG196831A1 (en) 2009-01-17 2014-02-13 Boomerang Systems Inc Automated storage system and transport vehicle
DK3150610T3 (da) * 2010-02-12 2019-11-04 Pfizer Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
CN103930931A (zh) 2011-09-23 2014-07-16 金泰克斯公司 用于后视镜显示的系统和方法
CN104053696B (zh) 2011-12-26 2015-07-08 胜技高分子株式会社 聚对苯二甲酸丁二醇酯树脂颗粒、以及该聚对苯二甲酸丁二醇酯树脂颗粒的制造方法
US9384339B2 (en) 2012-01-13 2016-07-05 Telecommunication Systems, Inc. Authenticating cloud computing enabling secure services
US9881309B2 (en) 2012-03-13 2018-01-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
KR101984831B1 (ko) 2013-01-31 2019-05-31 삼성전자 주식회사 반도체 패키지 및 그 제조 방법
CN103309115B (zh) 2013-05-30 2016-03-23 京东方科技集团股份有限公司 彩色电泳显示面板及其制造方法、显示装置
US9501163B2 (en) 2014-05-06 2016-11-22 Symbol Technologies, Llc Apparatus and method for activating a trigger mechanism
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
BR112012019050B1 (pt) 2021-12-21
LTC2534153I2 (lt) 2021-03-10
US20140243318A1 (en) 2014-08-28
EP3597651A1 (en) 2020-01-22
EP2534153A1 (en) 2012-12-19
KR20120127495A (ko) 2012-11-21
LUC00093I2 (enExample) 2019-12-24
CA2787881A1 (en) 2011-08-18
JP6371350B2 (ja) 2018-08-08
HUE030969T4 (hu) 2024-11-28
HUE030969T2 (en) 2017-06-28
NO2018039I1 (no) 2018-11-15
SG10201406805RA (en) 2014-11-27
SMT201600462B (it) 2017-03-08
SI2534153T1 (sl) 2017-01-31
EP3150610B1 (en) 2019-07-31
US9861638B2 (en) 2018-01-09
NZ601445A (en) 2014-08-29
SG182533A1 (en) 2012-08-30
US20150238504A1 (en) 2015-08-27
SMT201900634T1 (it) 2020-01-14
SMT201600462T1 (it) 2017-03-08
CY1118319T1 (el) 2017-06-28
RS55487B2 (sr) 2024-06-28
CN104876937A (zh) 2015-09-02
JP6640931B2 (ja) 2020-02-05
KR20190026043A (ko) 2019-03-12
BR112012019050A2 (pt) 2016-09-13
FR18C1049I1 (fr) 2019-02-15
DK2534153T4 (da) 2024-06-03
CA3024216C (en) 2021-03-30
JP2011168587A (ja) 2011-09-01
SI2534153T2 (sl) 2024-07-31
NL300958I2 (nl) 2018-12-19
CY2018031I2 (el) 2019-11-27
ES2607806T5 (es) 2024-10-07
FI2534153T4 (fi) 2024-06-26
PL2534153T5 (pl) 2024-11-18
AR080164A1 (es) 2012-03-21
PL3150610T3 (pl) 2020-02-28
JP2018199679A (ja) 2018-12-20
HUS1800046I1 (hu) 2018-12-28
US9045487B2 (en) 2015-06-02
EP2534153B2 (en) 2024-05-22
JP2021107460A (ja) 2021-07-29
DK2534153T3 (en) 2017-01-09
MX2012008911A (es) 2012-08-15
JP2020050671A (ja) 2020-04-02
BR112012019050A8 (pt) 2017-12-26
EP4166558A1 (en) 2023-04-19
CN102884066B (zh) 2015-01-07
PL2534153T3 (pl) 2017-08-31
LT2534153T (lt) 2016-12-12
LUC00093I1 (enExample) 2018-11-15
EP3150610A1 (en) 2017-04-05
MX343383B (es) 2016-11-03
US20200000821A1 (en) 2020-01-02
US8754072B2 (en) 2014-06-17
SI3150610T1 (sl) 2019-12-31
LTPA2018517I1 (lt) 2018-12-10
AR109356A2 (es) 2018-11-21
CN102884066A (zh) 2013-01-16
HUE047248T2 (hu) 2020-04-28
AU2011213944B2 (en) 2014-10-02
JP5745283B2 (ja) 2015-07-08
TWI545123B (zh) 2016-08-11
RU2570198C2 (ru) 2015-12-10
ES2607806T3 (es) 2017-04-04
US20120302550A1 (en) 2012-11-29
US20180092925A1 (en) 2018-04-05
TW201144316A (en) 2011-12-16
LT3150610T (lt) 2019-11-11
JP2015131858A (ja) 2015-07-23
AU2011213944A1 (en) 2012-08-09
EP2534153B1 (en) 2016-09-21
HK1176617A1 (zh) 2013-08-02
IL220921B (en) 2020-03-31
RU2012138892A (ru) 2014-03-20
CY2018031I1 (el) 2019-11-27
JP6013551B2 (ja) 2016-10-25
WO2011098971A1 (en) 2011-08-18
HRP20161742T4 (hr) 2024-07-05
CY1122218T1 (el) 2020-11-25
ES2753748T3 (es) 2020-04-14
KR102108226B1 (ko) 2020-05-08
PT2534153T (pt) 2016-12-27
PT3150610T (pt) 2019-11-11
HRP20191944T1 (hr) 2020-01-24
CA2787881C (en) 2019-01-08
HRP20161742T1 (hr) 2017-02-24
CN104876937B (zh) 2017-07-28
FR18C1049I2 (fr) 2021-01-08
JP2016216507A (ja) 2016-12-22
CA3024216A1 (en) 2011-08-18
RS55487B1 (sr) 2017-04-28
RS59494B1 (sr) 2019-12-31
US10278974B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
DK3150610T3 (da) Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
DK2211901T3 (da) Vaccination med multiple clader af h5-influenza-a-virus
DK2300560T3 (da) Termisk behandling af biomasse
DK2238255T3 (da) Replikationsdefekte arenavirusvektorer
DK2398785T3 (da) Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin
DK2300459T3 (da) Nye fenylpyrazinoner som kinasehæmmere
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2191831T3 (da) Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2296494T4 (da) Modermælkserstatning med fedtgradient
BRPI0907247A2 (pt) Métodos para preparar biopterina e para preparar tetraidrobiopterina
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2215050T3 (da) Fremgangsmåde til fremstilling af 2-hydroxy-5-phenylalkylaminobenzoesyrederivater og salte deraf
DK2175849T3 (da) Behandling af melanomer
DK2043656T3 (da) Hidtil ukendt medicinsk anvendelse af triazinderivater
DK2435443T3 (da) Aminopyrazoltriazolothiadiazolhæmmere af c-met-proteinkinase
DK2313967T3 (da) Resonansbaseret estimering af rotorposition
FI20080470A0 (fi) Liukupyyhe
NO20085304L (no) Glidebeslag
ITBS20080021U1 (it) Appendiabiti pieghevole
ES1068837Y (es) Mosquitera corredera
ES1068521Y (es) Colgador para posicion invertida
ES1070821Y (es) Pinza para perchas